Sign In
Buy ANIP
$75.23
+0.580 (+0.777%)
At Close: Jun 03, 2026
ANI Pharmaceuticals (ANIP) Q3 Earnings and Revenues Beat Estimates
09:12am, Monday, 01'st Nov 2021
ANI (ANIP) delivered earnings and revenue surprises of 42.25% and 3.50%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
ANI Pharmaceuticals to Discuss Third Quarter 2021 Financial Results on November 1, 2021
04:30pm, Friday, 29'th Oct 2021
BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its third quarter 2021 financial results on Mo
7 Overbought Stocks to Be Very Careful of Right Now
01:10pm, Friday, 01'st Oct 2021
While the market rally this year has been incredible, worrying developments suggest investors should watch out for overbought stocks. The post 7 Overbought Stocks to Be Very Careful of Right Now appea
ANI Pharmaceuticals to Present at Cantor Virtual Global Healthcare Conference 2021
04:30pm, Monday, 20'th Sep 2021
BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Finan
ANI Pharmaceuticals Announces Launch of Nebivolol Tablets
06:50am, Friday, 17'th Sep 2021
BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced the launch of Nebivolol Tablets, 2.5 mg, 5 mg, 10 mg, and 20 mg. ANI's Nebiv
BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq:ANIP) today announced that the Company's supplemental New Drug Application (“sNDA”) for Purifie
ANI Pharmaceuticals' (ANIP) CEO Nikhil Lalwani on Q2 2021 Results - Earnings Call Transcript
12:20pm, Friday, 06'th Aug 2021
ANI Pharmaceuticals' (ANIP) CEO Nikhil Lalwani on Q2 2021 Results - Earnings Call Transcript
ANI Pharmaceuticals Reports Second Quarter 2021 Results
07:24am, Friday, 06'th Aug 2021
BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced business highlights and financial results for the three and six months ended
Analysts Estimate ANI Pharmaceuticals (ANIP) to Report a Decline in Earnings: What to Look Out for
04:43pm, Friday, 30'th Jul 2021
ANI (ANIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ANI Pharmaceuticals Announces Refiling of Cortrophin sNDA with FDA
06:50am, Tuesday, 06'th Jul 2021
BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that the Company has re-filed its supplemental new drug application (“sNDA
A Low Valuation, High Growth Target: ANI Pharmaceuticals
02:09pm, Wednesday, 30'th Jun 2021
ANI's business growth rate could be on the cusp of a rapid acceleration.
ANI Pharmaceuticals to Present at the Raymond James Human Health Innovation Conference 2021
04:05pm, Tuesday, 15'th Jun 2021
BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Finan
Post Earnings Assessment On ANI Pharmaceuticals
12:05pm, Tuesday, 11'th May 2021
ANI Pharmaceuticals posted much better quarterly results than expected on Friday. This triggered a 15% rally in the stock that day, which the shares promptly gave back in yesterday's market sell-off.
ANI Pharmaceuticals, Inc. (ANIP) CEO Nikhil Lalwani on Q1 2021 Results - Earnings Call Transcript
12:52pm, Friday, 07'th May 2021
ANI Pharmaceuticals, Inc. (ANIP) CEO Nikhil Lalwani on Q1 2021 Results - Earnings Call Transcript
ANI Pharmaceuticals (ANIP) Q1 Earnings and Revenues Top Estimates
09:01am, Friday, 07'th May 2021
ANI (ANIP) delivered earnings and revenue surprises of 42.47% and 13.59%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
